Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

January 15, 2025--(BUSINESS WIRE)--Stoke Space, the rocket company building the world’s first 100% reusable medium-lift rocket, announced today that it has raised $260 million in new Series C ...

At present, the stock trades near $189 per share (Jan 6), up around 260% since the beginning of last year, 2024. In comparison, the S&P index has been up 25% over the same period. In contrast ...

Zydus Lifesciences Limited (Formerly known ... Oxemia. It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla ...

The St. Louis Cardinals talked a big game heading into the offseason, saying they were going to embark on a "reset", cutting payroll and giving opportunities to young players. However, the ...

The St. Louis Cardinals have been actively trying to trade third baseman Nolan Arenado. He has informed the team that he is willing to waive his no-trade clause to join the Boston Red Sox, but ...

Zydus Lifesciences Ltd share price was down by -3.65% from the previous closing price of ₹957.60. Who are peers of Zydus Lifesciences Ltd? The peers of Zydus Lifesciences Ltd are Sun ...